INGENIOUS Study: Identifying and Understanding Exacerbations of Fibrotic Lung Disease

Upcoming study
Expected to open March 2024
This study is currently recruiting
Expected to close March 2027
This study is closed
This study closed in March 2027
We will update this page with study results when available.
Information on study results are included below
This study closed in March 2027
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

Pulmonary fibrosis changes over time. Changes are often gradual, but sometimes someone affected by pulmonary fibrosis may experience a sudden change in their symptoms.

At diagnosis, it is not known if the changes will be gradual or faster than expected. There are currently no tests that can predict exacerbations, and the cause is often unclear. This means that there are no specific treatments for these deteriorations.

The aim of the study is to ask people to report any deterioration in symptoms, so these can be examined further with tests. This may help to identify specific markers in blood and sputum that can predict exacerbations or identify triggers that have led to deteriorations.


What is involved?

In this study, you will be asked to report any deterioration in your symptoms that is present for two days or more. The study team will aim to see you within 48 hours to collect samples, potentially treat and then follow up on any deterioration. You will also have a further follow up check at 1 week, 4 weeks and 12 weeks afterwards and will then be reviewed at 24 weeks. This may help researchers to identify specific markers in blood and sputum that can predict exacerbations or identify triggers that lead to deteriorations.

Different samples will be collected including: blood, sputum, oral rinse, saliva, nasal brushings, throat swab to check for viruses and stool and urine samples. You will also have your lung function measured using a hand-held spirometry machine and regular follow up through face to face and virtual consultations.

If your condition is stable and you do not experience any deterioration in your symptoms, you will have samples taken and lung function every six months. However, this will be combined with your routine hospital visits, so that you do not require a separate visit to provide the research samples.

Summary of involvement

Participation for 2-3 years

Report decline in your health and you will be seen by the research team within 48 hours

Collection of different samples

Lung function tests

Regular follow-up

Can I take part?

You may be able to take part if you are over the age of 18 years and have a diagnosis of pulmonary fibrosis.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the clinical trial team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

People over the age of 18 years

Diagnosis of pulmonary fibrosis

Willing and able to give written informed consent

People who have not had an acute exacerbation within the last 6 months

People who have not had antibiotic treatments for respiratory infections within the last 4 weeks

You will not be able to join the study of any of the following applies:

People who have other diseases that gives them a life expectancy of less than one year

People with sarcoidosis as the underlying cause of their fibrotic lung disease

People taking part in clinical trials who are receiving new drugs or therapies for lung fibrosis

What difference could taking part make?

Taking part in this study will help researcher to better understand the exacerbations and respiratory deteriorations that happen for people with scarring lung diseases. It may help to identify biomarkers and risk factors that can predict the development of exacerbations or respiratory deteriorations.

Taking part in research provides the opportunity to have an active involvement in your healthcare, help you to understand the disease more and the effects it has on your day to day life.  Research studies, such as this, have the potential to help develop new care strategies that could help improve the quality of people’s lives for those with pulmonary fibrosis, both now and in the future.

Where does the study take place?

Study locations

Royal Brompton Hospital

Imperial College Healthcare NHS Trust

If you are not currently receiving care at a different hospital but able willing and able to travel, you can speak to your current healthcare team about being referred to the ILD Team at the Royal Brompton Hospital or Imperial College Healthcare NHS Trust. This will enable you to be assigned to a consultant and take part in research studies.

How to take part

People who would like to find out more about taking part can email to express interest, or we would encourage you to discuss research opportunities with your healthcare team.

Further information

The summary on this page provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.

This study is supported by

Asthma and Lung UK
Study ID number:

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email